342 related articles for article (PubMed ID: 33794982)
1. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA.
Jiang F; Tang X; Tang C; Hua Z; Ke M; Wang C; Zhao J; Gao S; Jurczyszyn A; Janz S; Beksac M; Zhan F; Gu C; Yang Y
J Hematol Oncol; 2021 Apr; 14(1):54. PubMed ID: 33794982
[TBL] [Abstract][Full Text] [Related]
2. hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.
Hao W; Chen Z; Tang J; Yang R; Gao WQ; Xu H
J Transl Med; 2023 Nov; 21(1):861. PubMed ID: 38017546
[TBL] [Abstract][Full Text] [Related]
3. HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.
Jia C; Guo Y; Chen Y; Wang X; Xu Q; Zhang Y; Quan L
J Transl Med; 2022 Nov; 20(1):537. PubMed ID: 36401285
[TBL] [Abstract][Full Text] [Related]
4. Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit-induced long intergenic non-protein coding RNA 1833 N6-methyladenosine methylation promotes the non-small cell lung cancer progression via regulating heterogeneous nuclear ribonucleoprotein A2/B1 expression.
Li D; Fu Z; Dong C; Song Y
Bioengineered; 2022 Apr; 13(4):10493-10503. PubMed ID: 35441574
[TBL] [Abstract][Full Text] [Related]
5. Activation of the HNRNPA2B1/
Sun M; Shen Y; Jia G; Deng Z; Shi F; Jing Y; Xia S
J Cancer; 2023; 14(7):1242-1256. PubMed ID: 37215455
[TBL] [Abstract][Full Text] [Related]
6. HNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2.
Jiang J; Zhu J; Qiu P; Ni J; Zhu W; Wang X
Funct Integr Genomics; 2023 Dec; 24(1):3. PubMed ID: 38091112
[TBL] [Abstract][Full Text] [Related]
7. HNRNPA2B1 inhibited SFRP2 and activated Wnt-β/catenin via m6A-mediated miR-106b-5p processing to aggravate stemness in lung adenocarcinoma.
Rong L; Xu Y; Zhang K; Jin L; Liu X
Pathol Res Pract; 2022 May; 233():153794. PubMed ID: 35364458
[TBL] [Abstract][Full Text] [Related]
8. m
Liu R; Zhong Y; Chen R; Chu C; Liu G; Zhou Y; Huang Y; Fang Z; Liu H
Theranostics; 2022; 12(18):7760-7774. PubMed ID: 36451863
[No Abstract] [Full Text] [Related]
9. HNRNPA2B1 and HNRNPR stabilize ASCL1 in an m6A-dependent manner to promote neuroblastoma progression.
Hu T; Zeng C; Song Z; Liu Q; Chen S; Huang W; Ma Q; Li H
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167050. PubMed ID: 38331110
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop.
Liu Y; Wang JX; Nie ZY; Wen Y; Jia XJ; Zhang LN; Duan HJ; Shi YH
J Exp Clin Cancer Res; 2019 Oct; 38(1):439. PubMed ID: 31747963
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma.
Wang W; Li S
Recent Pat Anticancer Drug Discov; 2023 Oct; ():. PubMed ID: 37877146
[TBL] [Abstract][Full Text] [Related]
12. Fyn requires HnRNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer.
Chen ZY; Cai L; Zhu J; Chen M; Chen J; Li ZH; Liu XD; Wang SG; Bie P; Jiang P; Dong JH; Li XW
Carcinogenesis; 2011 Oct; 32(10):1419-26. PubMed ID: 21642356
[TBL] [Abstract][Full Text] [Related]
13. The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer.
Gupta A; Yadav S; Pt A; Mishra J; Samaiya A; Panday RK; Shukla S
Lab Invest; 2020 Dec; 100(12):1589-1601. PubMed ID: 32669614
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
15. HNRNPA2B1 Affects the Prognosis of Esophageal Cancer by Regulating the miR-17-92 Cluster.
Li K; Chen J; Lou X; Li Y; Qian B; Xu D; Wu Y; Ma S; Zhang D; Cui W
Front Cell Dev Biol; 2021; 9():658642. PubMed ID: 34277606
[TBL] [Abstract][Full Text] [Related]
16. hnRNPA2B1 Promotes Colon Cancer Progression via the MAPK Pathway.
Tang J; Chen Z; Wang Q; Hao W; Gao WQ; Xu H
Front Genet; 2021; 12():666451. PubMed ID: 34630502
[TBL] [Abstract][Full Text] [Related]
17. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol homeostasis confers glioma malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR.
Zhang J; Liu B; Xu C; Ji C; Yin A; Liu Y; Yao Y; Li B; Chen T; Shen L; Wu Y
Neuro Oncol; 2024 Apr; 26(4):684-700. PubMed ID: 38070488
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Ji G; Huang C; He S; Gong Y; Song G; Li X; Zhou L
Aging (Albany NY); 2020 Jul; 12(14):14863-14884. PubMed ID: 32710725
[TBL] [Abstract][Full Text] [Related]
20. Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer.
Yang Y; Wei Q; Tang Y; Yuanyuan Wang ; Luo Q; Zhao H; He M; Wang H; Zeng Q; Lu W; Xu J; Liu T; Yi P
Cancer Lett; 2020 Apr; 475():43-52. PubMed ID: 32006618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
